Nuvectis Pharma (NVCT) Institutional Ownership $7.78 +0.05 (+0.65%) Closing price 04:00 PM EasternExtended Trading$7.98 +0.20 (+2.57%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Nuvectis Pharma (NASDAQ:NVCT)CurrentInstitutional OwnershipPercentage96.77%Number ofInstitutional Buyers(last 12 months)19TotalInstitutional Inflows(last 12 months)$7.41MNumber ofInstitutional Sellers(last 12 months)5TotalInstitutional Outflows(last 12 months)$438.30K Get NVCT Insider Trade Alerts Want to know when executives and insiders are buying or selling Nuvectis Pharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data NVCT Institutional Buying and Selling by Quarter Nuvectis Pharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails7/24/2025 Baldwin Wealth Partners LLC MA350,461$2.62M0.2%-2.2%1.678% 6/27/2025Goldman Sachs Group Inc.45,608$446K0.0%N/A0.218% 5/19/2025Jane Street Group LLC42,299$413K0.0%N/A0.202% 5/16/2025Goldman Sachs Group Inc.45,608$446K0.0%N/A0.218% 5/15/2025OMERS ADMINISTRATION Corp32,882$321K0.0%N/A0.139% 5/1/2025Austin Wealth Management LLC40,250$393K0.1%N/A0.172% 4/30/2025Iridian Asset Management LLC CT253,972$2.48M0.8%N/A1.086% 4/23/2025Oppenheimer & Co. Inc.41,000$401K0.0%+64.0%0.175% 4/14/2025 Baldwin Wealth Partners LLC MA358,461$3.50M0.2%+0.7%1.532% 4/11/2025 Blue Zone Wealth Advisors LLC10,424$102K0.0%N/A0.045% Get the Latest News and Ratings for NVCT and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Nuvectis Pharma and its competitors with MarketBeat's FREE daily newsletter. 2/17/2025Squarepoint Ops LLC19,071$103K0.0%N/A0.099% 2/17/2025Two Sigma Investments LP18,570$100K0.0%-30.7%0.096% 2/17/2025Millennium Management LLC29,698$161K0.0%-56.6%0.154% 2/17/2025Cubist Systematic Strategies LLC6,294$34K0.0%N/A0.033% 2/14/2025Northern Trust Corp25,725$139K0.0%+68.7%0.133% 2/13/2025Marshall Wace LLP124,571$674K0.0%+191.0%0.645% 2/12/2025Edmond DE Rothschild Holding S.A.15,170$82K0.0%-20.9%0.079% 2/12/2025 Baxter Bros Inc.15,000$81K0.0%+20.0%0.078% 2/5/2025Oppenheimer & Co. Inc.25,000$135K0.0%N/A0.129% 1/30/2025Nations Financial Group Inc. IA ADV13,500$73K0.0%+35.0%0.070% 1/28/2025 Forbes J M & Co. LLP59,000$319K0.0%+21.9%0.305% 1/22/2025 Baldwin Wealth Partners LLC MA355,961$1.93M0.1%+104.4%1.842% 11/16/2024Geode Capital Management LLC79,716$501K0.0%+49.8%0.413% 11/5/2024 GSA Capital Partners LLP50,129$315K0.0%+3.7%0.269% 11/5/2024Nations Financial Group Inc. IA ADV10,000$63K0.0%N/A0.054% 10/25/2024Iridian Asset Management LLC CT55,380$348K0.1%N/A0.297% 9/16/2024Point72 Asia Singapore Pte. Ltd.9,203$58K0.0%N/A0.050% 8/15/2024Point72 Asia Singapore Pte. Ltd.9,203$58K0.0%N/A0.050% 8/14/2024Marshall Wace LLP33,868$214K0.0%-32.4%0.185% 8/9/2024Renaissance Technologies LLC74,500$472K0.0%+20.7%0.406% 7/16/2024 Baxter Bros Inc.12,500$79K0.0%N/A0.068% 7/12/2024 Baldwin Brothers LLC MA168,630$1.07M0.1%+9.4%0.918% 5/10/2024Vanguard Group Inc.298,800$2.45M0.0%+1.5%1.626% 4/18/2024 Blue Zone Wealth Advisors LLC14,350$118K0.0%N/A0.081% 2/12/2024Edmond DE Rothschild Holding S.A.19,170$160K0.0%N/A0.111% 1/30/2024Strs Ohio6,200$51K0.0%+59.0%0.036% 1/8/2024 Baldwin Brothers LLC MA142,040$1.19M0.1%+22.0%0.820% 11/2/2023 Forbes J M & Co. LLP34,000$438K0.1%-49.3%0.197% 10/26/2023Strs Ohio3,900$50K0.0%+178.6%0.023% 10/10/2023 Baldwin Brothers LLC MA116,380$1.50M0.1%+29.2%0.675% The Private Market Surge Is Coming in 2025 (Ad)The most lucrative investment opportunities are reserved for a select category of investor. They're private. They're quiet. And they're often available exclusively to accredited investors operating outside the noise of the public markets. We're talking about off-market placements, early venture deals, private credit, and pre-IPO shares—the kind of plays that can generate outsized gains before Wall Street catches wind. Here's the reality: having access is only the beginning. These deals can be opaque, rushed, and filled with hidden risk. That's why we created something exclusively for investors like you—the 2025 Accredited Investor Playbook.Get your copy now: [Access the 2025 Accredited Investor Playbook]8/10/2023Hollencrest Capital Management3,040$49K0.0%N/A0.019% 8/4/2023American International Group Inc.3,298$53K0.0%N/A0.021% 8/3/2023 Forbes J M & Co. LLP67,000$1.07M0.1%N/A0.418% 8/2/2023Bank of Montreal Can11,012$200K0.0%N/A0.069% 7/14/2023 Baldwin Brothers LLC MA90,061$1.44M0.1%-37.4%0.563% 5/11/2023Edmond DE Rothschild Holding S.A.24,570$322K0.0%N/A0.167% 4/21/2023 Baldwin Brothers LLC MA143,800$1.89M0.2%+7.9%0.975% 11/4/2022Ronit Capital LLP562,547$3.99M5.4%+34.2%3.843% 10/14/2022 Baldwin Brothers LLC MA133,000$943K0.1%+9.9%0.908% 8/4/2022Ronit Capital LLP419,282$4.70M6.7%-23.8%3.297% 7/18/2022 Baldwin Brothers LLC MA121,000$1.36M0.2%N/A0.951% 5/11/2022Ronit Capital LLP550,000$4.08M5.1%N/A4.325% (Data available from 1/1/2016 forward) NVCT Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NVCT shares? During the previous two years, 28 institutional investors and hedge funds held shares of Nuvectis Pharma. The most heavily invested institutionals were Baldwin Wealth Partners LLC MA ($2.62M), Iridian Asset Management LLC CT ($2.48M), Vanguard Group Inc. ($2.45M), Baldwin Brothers LLC MA ($1.07M), Marshall Wace LLP ($674K), Geode Capital Management LLC ($501K), and Renaissance Technologies LLC ($472K).Learn more on Nuvectis Pharma's institutional investors. What percentage of Nuvectis Pharma's stock is owned by institutional investors? 96.77% of Nuvectis Pharma's stock is owned by institutional investors. Learn more on NVCT's institutional investor holdings. Which institutional investors have been buying Nuvectis Pharma's stock? Of the 26 institutional investors that purchased Nuvectis Pharma's stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Iridian Asset Management LLC CT ($309.35K), Baldwin Wealth Partners LLC MA ($184.33K), Goldman Sachs Group Inc. ($91.22K), Marshall Wace LLP ($81.76K), Forbes J M & Co. LLP ($77.60K), Baldwin Brothers LLC MA ($66.48K), and Jane Street Group LLC ($42.30K). How much institutional buying is happening at Nuvectis Pharma? Institutional investors have bought a total of 955,432 shares in the last 24 months. This purchase volume represents approximately $7.41M in transactions. Which of Nuvectis Pharma's major shareholders have been selling company stock? The following institutional investors have sold Nuvectis Pharma stock in the last 24 months: Millennium Management LLC ($38.80K), Marshall Wace LLP ($16.20K), Two Sigma Investments LP ($8.22K), Baldwin Wealth Partners LLC MA ($8K), and Edmond DE Rothschild Holding S.A. ($4K). How much institutional selling is happening at Nuvectis Pharma? Institutional investors have sold a total of 75,216 shares in the last 24 months. This volume of shares sold represents approximately $438.30K in transactions. Related Companies MRVI Major Shareholders IOVA Major Shareholders URGN Major Shareholders TLRY Major Shareholders TNGX Major Shareholders STOK Major Shareholders PRME Major Shareholders DNTH Major Shareholders PHAT Major Shareholders UPB Major Shareholders This page (NASDAQ:NVCT) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvectis Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvectis Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.